Latest Rofecoxib Stories
Vytorian, a controversial new drug that fights cholesterol, might not be living up to initial expectations for battling heart disease, according to a leading panel of experts who are suggesting patients stick with statins.
Dr. Alastair J.J. Wood, drug development authority, frequent advisor to the Food and Drug Administration (FDA) and former Assistant Vice Chancellor for Research at Vanderbilt University, was recently named to the Board of Directors of the Critical Path Institute.
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
By Wagenitz, Andreas Mueller, Edgar A; Frentzel, A
How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx?
By Saudan, M; Saudan, P; Perneger, T; Riand, N; Et al We examined whether a selective cyclo-oxygenase-2 (COX-2) inhibitor (celecoxib) was as effective as a non-selective inhibitor (ibuprofen) for the prevention of heterotopic ossification following total hip replacement.
U.S. firm Merck said Monday its new COX 2 painkiller -- in the same class as Vioxx -- has a cardiac risk similar to Novartis' Voltaren.
NEW YORK (Reuters) - A federal judge overturned a $50 million award handed down by a jury against Merck & Co. Inc. earlier this month in a case of a former FBI agent who had blamed the withdrawn painkiller Vioxx for his heart attack. In a written ruling, U.S.
NEW YORK (Reuters) - A federal judge overturned a $50 million award handed down by jury against Merck & Co. earlier this month in a case of a former FBI agent who had blamed the withdrawn painkiller Vioxx for his heart attack, the Wall Street Journal reported on its web site on Wednesday.
Merck & Co. on Wednesday said the experimental arthritis drug Arcoxia, in a study, met its main goal of causing no more blood clot-related heart attacks than a standard treatment, but more patients taking Arcoxia withdrew from the trial due to serious side effects.
- An imitative word; an onomatopoetic word.